Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05912582

Enrollment

Registered

2023-06-22

Start date

2025-12-25

Completion date

2028-12-25

Last updated

2025-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Keywords

Nasopharyngeal Carcinoma, Biomarker, Spatial Transcriptomics

Brief summary

This clinical research aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma.

Detailed description

Primary endpoint: Evaluation of the major pathological response of nasopharyngeal carcinoma patients. Secondary endpoint: Evaluation of failure-free survival and overall survival of nasopharyngeal carcinoma patients. Outline: This is a prospective observational study. Patients of nasopharyngeal carcinoma undergo inductive chemotherapy and concurrent chemoradiotherapy. Whole blood is obtained from patients when recruited, completing 10, 20, 32 fractions of radiation therapy, 3 months after radiation therapy and disease progression. Tumor tissue specimens are obtained from patients when recruited and disease progression. The samples are analyzed for biomarkers and spatial transcriptomics. The biomarkers and spatial transcriptomics are correlated with clinical outcomes (major pathological response, progression-free survival, overall survival, tumor response to treatment, distant metastasis, recurrence and death). The analysis aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma. This will lead to the definition of risk groups and stratification of patients and will help in precision medicine of nasopharyngeal carcinoma.

Interventions

RADIATIONIntensity modulated radiation therapy (IMRT) combined with chemotherapy

Intensity modulated radiation therapy (IMRT) combined with chemotherapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Patients with newly histologically confirmed nasopharyngeal carcinoma 2. No evidence of distant metastasis (M0) 3. Written informed consent

Exclusion criteria

Treatment with palliative intent

Design outcomes

Primary

Measure	Time frame
major pathological response	3 months after radiation therapy

Secondary

Measure	Time frame
Progression-free Survival	2 years after radiation therapy
Overall Survival	2 years after radiation therapy

Countries

China

Contacts

Primary ContactLirong Wu

wulirong126@126.com+86-13701588737

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026